Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825564 | 0.86 | PGR (0.49) | DPP4HDAC8HDAC6SPRPGR | |
| SCHEMBL3825571 | 0.86 | PGR (0.49) | DPP4HDAC8HDAC6SPRPGR | |
| SCHEMBL13238912 | 0.84 | ALDH1A1 (0.53) | DPP4HDAC8HDAC6PGRCYP2D6 | |
| SCHEMBL3038785 | 0.83 | TRPA1 (0.48) | AR | |
| SCHEMBL16321644 | 0.83 | TRPA1 (0.48) | AR | |
| SCHEMBL3024142 | 0.80 | PGR (0.51) | DPP4HDAC8HDAC6PGRCYP2D6 | |
| SCHEMBL3023921 | 0.80 | MLNR (0.50) | DPP4HDAC8HDAC6SPR | |
| SCHEMBL380969 | 0.79 | ALDH1A1 (0.61) | DPP4HDAC8HDAC6L3MBTL1 | |
| SCHEMBL27480803 | 0.78 | HDAC1 (0.54) | HDAC8HDAC6SPRL3MBTL1IDO1 | |
| SCHEMBL3037282 | 0.78 | PGR (0.51) | DPP4HDAC8HDAC6PGRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216813-A1 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-2094269-A1 | PYRROLIDINANILINES | Smithkline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1954133-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008077089-A1 | PYRROLIDINANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216813-A1 | PYRROLIDINEANILINES | PGF, ARG1, CYP19A1 | DPP4 3862/4885HDAC8 667/4885HDAC6 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.